STEM CELL INNOVATIONS, INC.

STEM CELL INNOVATIONS, INC. (CIK 351532) operates within the Biological Products sector that spans an array of regenerative and therapeutic applications, focusing on pioneering adult stem cell technologies; it develops proprietary cell-based treatments, supportive biologics, and related services designed for researchers, specialty clinics, and pharmaceutical partners seeking advanced regenerative options in a tightly regulated environment. The company’s work hinges on high-purity cell isolation, expansion protocols, and clinical-grade manufacturing that align with stringent FDA biologics standards, positioning it to serve a niche of institutions navigating the complexities of therapeutic development and compassionate-use programs. While recent revenue disclosure opportunities have been limited—the latest SEC submission dates to a Form 10-Q filed in November 1999—the company’s evolution still depends on securing sufficient capital, managing long lead times for trials, and maintaining compliance with Good Manufacturing Practices and potential shifts in regenerative medicine oversight. Investors and stakeholders can view live SEC filings on Earnings Feed.

Source: Earnings Feed research · last updated 11/24/2025